Pomegranate phytosterol (β-sitosterol) and polyphenolic antioxidant (punicalagin) addition to statin, significantly protected against macrophage foam cells formation

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 110-117

  Rosenblat, Mira ^a   Volkova, Nina ^a   Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Sitosterol; Cholesterol biosynthesis; Macrophages; Oxidative stress; Pomegranate juice; Punicalagin; Simvastatin

Indexed keywords

ARYLDIALKYLPHOSPHATASE 2; GLUTATHIONE; POMEGRANATE PHYTOSTEROL; PUNICALAGIN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SITOSTEROL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; MACROPHAGE; MONONUCLEAR PHAGOCYTE; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; POMEGRANATE JUICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTIOXIDANTS; BEVERAGES; CELLS, CULTURED; CHOLESTEROL; DRUG COMBINATIONS; FOAM CELLS; HYDROLYZABLE TANNINS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; PUNICACEAE; SIMVASTATIN; SITOSTEROLS;

EID: 84871375203     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.054     Document Type: Article

References (53)

1. Tiwari R.L., Singh Y., Barthwal M.K. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev 2008, 28:483-544.
2. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
3. Aviram M. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins. Antioxid Redox Signal 1999, 1:585-594.
4. Lang P.D., Insull W. Lipid droplets in atherosclerotic fatty streaks of human aorta. J Clin Invest 1970, 49:1479-1488.
5. Lundberg B. Chemical composition and physical state of lipid deposits in atherosclerosis. Atherosclerosis 1985, 56:93-110.
6. Bozentowicz-Wikarek M., Kocełak P., Smertka M., Olszanecka-Glinianowicz M., Chudek J. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis - guidelines vs. reality. Pharmacol Rep 2012, 64:377-385.
7. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol 2012, 73:518-535.
8. Lupattelli G., Siepi D., De Vuono S., et al. Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia. Life Sci 2012, 90:846-850.
9. Sobal G., Sinzinger H. Effect of simvastatin on the oxidation of native and modified lipoproteins. Biochem Pharmacol 2005, 70:1185-1191.
10. Goldfine A.B. Statins: is it really time to reassess benefits and risks?. N Engl J Med 2012, 366:1752-1755.
11. Ostlund R.E. Phytosterols in human nutrition. Annu Rev Nutr 2002, 22:533-549.
12. Moruisi K.G., Oosthuizen W., Opperman A.M. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr 2006, 25:41-48.
13. Malinowski J.M., Gehret M.M. Phytosterols for dyslipidemia. Am J Health Syst Pharm 2010, 67:1165-1173.
14. Ortega R.M., Palencia A., López-Sobaler A.M. Improvement of cholesterol levels and reduction of cardiovascular risk via the consumption of phytosterols. Br J Nutr 2006, 96(Suppl. 1):S89-S93.
15. Rocha M., Banuls C., Bellod L., Jover A., Victor V.M., Hernandez-Mijares A. A review on the role of phytosterols: new insights into cardiovascular risk. Curr Pharm Des 2011, 17:4061-4075.
16. Marangoni F., Poli A. Phytosterols and cardiovascular health. Pharmacol Res 2010, 61:193-199.
17. De Jong A., Plat J., Bast A., Godschalk R.W., Basu S., Mensink R.P. Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. Eur J Clin Nutr 2008, 62:263-273.
18. Scholle J.M., Baker W.L., Talati R., Coleman C.I. The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis. J Am Coll Nutr 2009, 28:517-524.
19. Miettinen T.A., Gylling H. The effects of statins and sitosterols: benefit or not?. Curr Atheroscler Rep 2009, 11:23-27.
20. Thompson G.R. Additive effects of plant sterol and stanol esters to statin therapy. Am J Cardiol 2005, 96:37D-39D.
21. Kulkarni A.P., Mahal H.S., Kapoor S., Aradhya S.M. In vitro studies on the binding, antioxidant, and cytotoxic actions of punicalagin. J Agric Food Chem 2007, 55:1491-1500.
22. Seeram N.P., Adams L.S., Henning S.M., et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005, 16:360-367.
23. Lin C.C., Hsu Y.F., Lin T.C. Antioxidant and free radical scavenging effects of the tannins of Terminalia catappa L. Anticancer Res 2001, 21:237-243.
24. Moreno J.J. Effect of olive oil minor components on oxidative stress and arachidonic acid mobilization and metabolism by macrophages RAW 264.7. Free Radic Biol Med 2003, 35:1073-1081.
25. Chartoumpekis D., Ziros P.G., Psyrogiannis A., Kyriazopoulou V., Papavassiliou A.G., Habeos I.G. Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway. Biochem Biophys Res Commun 2010, 396:463-466.
26. Fuhrman B., Volkova N., Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem 2005, 16:570-576.
27. Awad A.B., Williams H., Fink C.S. Effect of phytosterols on cholesterol metabolism and MAP kinase in MDA-MB-231 human breast cancer cells. J Nutr Biochem 2003, 14:111-119.
28. Van Elswijk D.A., Schobel U.P., Lansky E.P., Irth H., van der Greef J. Rapid dereplication of estrogenic compounds in pomegranate (Punica granatum) using on-line biochemical detection coupled to mass spectrometry. Phytochemistry 2004, 65:233-241.
29. Mori-Okamoto J., Otawara-Hamamoto Y., Yamato H., Yoshimura H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J Ethnopharmacol 2004, 92:93-101.
30. Blois M.S. Antioxidant determination by the use of a stable free radical. Nature 1958, 181:1199-1200.
31. 2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003, 23:461-467.
32. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
33. LeBel C.P., Ischiropoulos H., Bondy S.C. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992, 5:227-231.
34. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: application to mammalian blood and other tissues. Anal Biochem 1969, 27:502-522.
35. Altenhöfer S., Witte I., Teiber J.F., et al. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J Biol Chem 2010, 285:24398-24403.
36. Horke S., Witte I., Wilgenbus P., Krüger M., Strand D., Förstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007, 115:2055-2064.
37. Ng C.J., Wadleigh D.J., Gangopadhyay A., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001, 76:44444-44449.
38. Field F.J., Born E., Mathur S.N. Effect of micellar beta-sitosterol on cholesterol metabolism in CaCo-2 cells. Lipid Res 1997, 38:348-360.
39. Alberts A.W. Lovastatin and simvastatin - inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology 1990, 77(Suppl. 4):14-21.
40. Cohen L.H., van Vliet A., Roodenburg L., Jansen L.M., Griffioen M. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Biochem Pharmacol 1993, 45:2203-2208.
41. Hoffman R., Brook J.G., Aviram M. Hypolipidemic therapy reduces lipoprotein susceptibility to undergo lipid peroxidation; in-vitro and ex-vivo studies. Atherosclerosis 1992, 93:105-113.
42. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998, 138:271-280.
43. Hussein O., Shneider J., Rosenblat M., Aviram M. Further contributions of valsartan to antioxidative effect of fluvastatin therapy against LDL oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 2002, 40:28-34.
44. Fuhrman B., Shiner M., Volkova N., Aviram M. Cell-induced copper ion-mediated low density lipoprotein oxidation increases during in vivo monocyte-to-macrophage differentiation. Free Radic Biol Med 2004, 37:259-271.
45. Fuhrman B., Judith O., Keidar S., Ben-Yaish L., Kaplan M., Aviram M. Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radic Biol Med 1997, 23:34-46.
46. Vivancos M., Moreno J.J. Beta-sitosterol modulates antioxidant enzyme response in RAW 264.7 macrophages. Free Radic Biol Med 2005, 39:91-97.
47. Rosenblat M., Draganov D., Watson C.E., Bisgaier C.L., La Du B.N., Aviram M. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:468-474.
48. Arii K., Suehiro T., Ota K., et al. Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 2009, 202:439-445.
49. Nagila A., Permpongpaiboon T., Tantrarongroj S., et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009, 61:892-898.
50. Poulakou M.V., Paraskevas K.I., Vlachos I.S., et al. Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. Angiology 2008, 59:137-144.
51. Tomas M., Senti M., Garcia-Faria F., et al. Effect of simvastatin therapy on paraoxonase activity and related proteins in FH patients. Arterioscler Thromb Vasc Biol 2000, 20:2113-2119.
52. Aviram M., Rosenblat M., Gaitini D., et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004, 23:423-433.
53. Rozenberg O., Shih D.M., Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005, 181:9-18.